Publication:
One-year follow-up of cystic fibrosis patients who cannot reach the modulator therapies although having indications: What are their losses?

Simple item page
dc.contributor.authorUytun, S.
dc.contributor.authorPolat, S. Eryılmaz
dc.contributor.authorTabakçı, S. Özkan
dc.contributor.authorCinel, G.
dc.contributor.authorEmiralioğlu, N.
dc.contributor.authorYalçın, E.
dc.contributor.authorKiper, N.
dc.contributor.authorSen, V
dc.contributor.authorAltıntaş, D. U.
dc.contributor.authorÇokuğraş, H.
dc.contributor.authorKılınç, A. A.
dc.contributor.authorYazan, H.
dc.contributor.authorÇollak, A.
dc.contributor.authorUzuner, S.
dc.contributor.authorÜnal, G.
dc.contributor.authorYılmaz, A., I
dc.contributor.authorÇelik, S.
dc.contributor.authorDamadoğlu, E.
dc.contributor.authorIrmak, I.
dc.contributor.authorDemir, E.
dc.contributor.authorÖztürk, G.
dc.contributor.authorBaşaran, E.
dc.contributor.authorBingöl, A.
dc.contributor.authorSapan, Nihat
dc.contributor.authorAslan, A. T.
dc.contributor.authorAsfuroğlu, P.
dc.contributor.authorHarmancı, K.
dc.contributor.authorKöse, M.
dc.contributor.authorHangül, M.
dc.contributor.authorÖzdemir, A.
dc.contributor.authorÖzcan, G.
dc.contributor.authorGayretli, Z. G.
dc.contributor.authorKeskin, O.
dc.contributor.authorYüksel, H.
dc.contributor.authorÖzdoğan, S.
dc.contributor.authorTopal, E.
dc.contributor.authorÇaltepe, G.
dc.contributor.authorCan, D.
dc.contributor.authorEkren, P. Korkmaz
dc.contributor.authorKılıç, M.
dc.contributor.authorSüleyman, A.
dc.contributor.authorEyüboğlu, T. Şişmanlar
dc.contributor.authorPekcan, S.
dc.contributor.authorÇobanoğlu, N.
dc.contributor.authorÇakır, E.
dc.contributor.authorÖzçelik, U.
dc.contributor.authorDoğru, D.
dc.contributor.buuauthorSAPAN, NİHAT
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentPediatri Alerji ve İmmünoloji Bölümü
dc.contributor.researcheridFUI-8766-2022
dc.date.accessioned2024-12-03T08:27:50Z
dc.date.available2024-12-03T08:27:50Z
dc.date.issued2022-09-04
dc.descriptionBu çalışma, 04-06 Eylül, 2022 tarihlerinde Barcelona[İspanya]’da düzenlenen International Congress of the European-Respiratory-Society (ERS) Kongresi‘nde bildiri olarak sunulmuştur.
dc.description.sponsorshipEuropean Respiratory Soc
dc.identifier.doi10.1183/13993003.congress-2022.2642
dc.identifier.eissn1399-3003
dc.identifier.issn0903-1936
dc.identifier.urihttps://doi.org/10.1183/13993003.congress-2022.2642
dc.identifier.urihttps://publications.ersnet.org/content/erj/60/suppl66/2642
dc.identifier.urihttps://hdl.handle.net/11452/48822
dc.identifier.volume60
dc.identifier.wos000893392403484
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherEuropean Respiratory Soc Journals
dc.relation.journalEuropean Respiratory Journal
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectRespiratory system
dc.titleOne-year follow-up of cystic fibrosis patients who cannot reach the modulator therapies although having indications: What are their losses?
dc.typeMeeting Abstract
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Pediatri Alerji ve İmmünoloji Bölümü
local.indexed.atWOS
relation.isAuthorOfPublicationcc312521-b6b8-4031-a0a0-b06b35291a1c
relation.isAuthorOfPublication.latestForDiscoverycc312521-b6b8-4031-a0a0-b06b35291a1c

Files

Collections

İndeksli Yayınlar / Indexed Publications